Glucosamine and Chondroitin Effects
N/A
20 Years
55 Years
20 Years
55 Years
Open (Enrolling)
Both
Inflammation
Both
Inflammation
Trial Information
Glucosamine and Chondroitin Effects
Use of glucosamine and chondroitin have been associated with reduced cancer and overall
mortality. The aim of this study is to determine whether a common starting dose of
glucosamine and chondroitin (1500 mg/d + 1200 mg/d, respectively) reduces systemic
inflammation as reflected by a reduction in high sensitivity C-reactive protein.
Inclusion Criteria:
- Healthy
- Overweight (body mass index kg/m2 (BMI) between 25 and 32.5)
- Non-smoking men and women
- Aged 20-55y
Exclusion Criteria:
- Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or
inflammatory conditions (including autoimmune and inflammatory diseases)
- Pregnancy or lactation
- Currently on a weight-loss diet
- BMI (body mass index) < 25 or > 30
- Alcohol intake of greater than 2 drinks/day
- Current use of prescription or over-the-counter medications, (Excluding oral
contraceptives and hormone-secreting IUDs), including use of aspirin or NSAIDs more
than 2 days per week
- Abnormal renal, liver or metabolic test
- Inability to swallow pills
- Known allergy to shellfish
- Not willing to take pills made from shellfish or animal sources
- Intention to relocate out of study area within next 4 months
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Outcome Measure:
hsCRP
Outcome Description:
hsCRP is a biomarker of systemic inflammation
Outcome Time Frame:
1 year
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
7798
NCT ID:
NCT01682694
Start Date:
September 2012
Completion Date:
August 2013
Related Keywords:
- Inflammation
- Inflammation
Name | Location |
|---|---|
| Fred Hutchinson Cancer Research Center | Seattle, Washington 98109 |
